Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Edesa Biotech, Inc. | stellarbiotechnologiesinc.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) February 9, 2015
STELLAR BIOTECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
|
British Columbia, Canada
|
000-54598
|
N/A
|
||
|
(State or other jurisdiction
|
(Commission
|
(I.R.S. Employer
|
||
|
of incorporation)
|
File Number)
|
Identification No.)
|
332 E. Scott Street
Port Hueneme, California 93041
(Address of principal executive offices) (Zip Code)
(805) 488-2800
(Registrant’s telephone number, including area code)
Not applicable.
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Explanatory Note
This Amendment No. 1 to Form 8-K amends the Current Report on Form 8-K filed with the Securities and Exchange Commission by Stellar Biotechnologies, Inc. (the “Company”) on February 9, 2015 (the “Original Filing”). This Amendment No. 1 is being filed to correct certain typographical and formatting errors contained in the Original Filing, including the cover page of the Original Filing. This Amendment No. 1 amends and restates the Original Filing in its entirety for the sake of completeness.
Item 2.02 Results of Operations and Financial Condition.
On February 9, 2015, the Company issued a press release announcing its financial results for its fiscal quarter ended December 31, 2014.
The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information furnished therein shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that Section.
Item 9.01 Financial Statements and Exhibits.
|
Exhibit No.
|
Description
|
|
|
Press release issued by Stellar Biotechnologies, Inc. dated February 9, 2015.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Stellar Biotechnologies, Inc.
Date: February 11, 2015 By: /s/ Kathi Niffenegger
Name: Kathi Niffenegger
Title: Chief Financial Officer
EXHIBIT INDEX
|
Exhibit No.
|
Description
|
|
|
Press release issued by Stellar Biotechnologies, Inc. dated February 9, 2015.
|